Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yale Hemorrhagic Stroke Project

This article was originally published in The Tan Sheet

Executive Summary

Enrollment expected to be complete by the end of May, the Consumer Healthcare Products Association tells FDA in an April 30 letter. The CHPA-sponsored study will investigate the possible relationship between phenylpropanolamine and increased risk of hemorrhagic stroke. Expected enrollment is 700 cases and 1,400 controls; so far, 692 cases have been enrolled and eligibility reviews have been completed for 558 enrollees
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel